Takeda and SGC Announce a Collaboration Agreement Using Patient Tissue-Based Assays for Clinical Target Validation in Inflammatory Bowel Disease

OSAKA, Japan & SAN DIEGO & STOCKHOLM–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), Karolinska Institutet (“KI”) and The Structural Genomics Consortium (“SGC”) today announced a combined pre-competitive and …
( read original story …)